

diabetes

A JOURNAL OF
THE AMERICAN
DIABETES
ASSOCIATION®

PERSPECTIVES IN DIABETES

ATP-Sensitive K⁺ channels in pancreatic β -cells: spare-channel hypothesis D.L. COOK,
L.S. SATIN, M.L.J. ASHFORD, AND C.N. HALES 495

ORIGINAL ARTICLES

Minimal effects of phorbol esters on glucose transport and insulin sensitivity of rat skeletal
muscle M.O. SOWELL, M.K. TREUTELAAR, C.F. BURANT, AND M.G. BUSE 499

Proteinuria and activated T-lymphocytes in diabetic nephropathy J.J. BENDING,
A. LOBO-YEO, D. VERGANI, AND G.C. VIBERTI 507

Regulation of whole-body leucine metabolism with insulin during mixed-meal absorption in
normal and diabetic humans P. TESSARI, G. PEHLING, S.L. NISSEN, J.E. GERICH, F.J. SERVICE,
R.A. RIZZA, AND M.W. HAYMOND 512

Role of host immune system in BB/Wor rat: predisposition to diabetes resides in bone
marrow K. NAKANO, J.P. MORDES, E.S. HANDLER, D.L. GREINER, AND A.A. ROSSINI 520

Counterregulatory hormone responses preserved after long-term intravenous insulin infusion
compared to continuous subcutaneous insulin infusion M. GULAN, K. PERLMAN, M. SOLE,
A.M. ALBISSER, AND B. ZINMAN 526

Molecular mechanisms in basement membrane complications of diabetes: alterations in
heparin, laminin, and type IV collagen association J.F. TARSIO, L.A. REGER, AND L.T. FURCHT 532

Modulation of insulin activity by hydrochloride salts J.C. AGHARANYA 540

Bacterial phagocytosis and intracellular killing by alveolar macrophages in BB rats
A.A.F. SIMA, S.J. O'NEILL, D. NAIMARK, S. YAGIHASHI, AND D. KLASS 544

Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human
monocyte-derived macrophages M.F. LOPES-VIRELLA, R.L. KLEIN, T.J. LYONS, H.C. STEVENSON,
AND J.L. WITZTUM 550

Glomerular Na⁺-K⁺-ATPase activity in acute and chronic diabetes and with aldose
reductase inhibition M.P. COHEN AND H. KLEPSEK 558

Control of glucose phosphorylation and glucose usage in clonal insulinoma cells
T. SHIMIZU, B.B. KNOWLES, AND F.M. MATSCHINSKY 563

Insulin gene in familial NIDDM: lack of linkage in Utah Mormon Pedigrees S.C. ELBEIN,
L. CORSETTI, D. GOLDFAR, M. SKOLNICK, AND M.A. PERMUTT 569

Composition changes in hepatic microsomal cytochrome P-450 during onset of streptozocin-
induced diabetes and during insulin treatment L.V. FAVREAU AND J.B. SCHENKMAN 577

Autoradiographic evidence for insulin and insulin-like growth factor binding to early mouse
embryos B.A. MATTSON, I.Y. ROSENBLUM, R.M. SMITH, AND S. HEYNER 585

Day-long integrated serum insulin and C-peptide profiles in patients with NIDDM: correlation
with urinary C-peptide excretion W.T. GARVEY, J.M. OLEFSKY, A.H. RUBENSTEIN,
AND O.G. KOLTERMAN 590

Severe diabetes induced in subtotaly depancreatized dogs by sustained hyperglycemia
T. IMAMURA, M. KOFFLER, J.H. HELDERMAN, D. PRINCE, R. THIRLBY, L. INMAN, AND R.H. UNGER 600

Plasma lipolytic activity: relationship to postheparin lipolytic activity and evidence for
metabolic regulation R.H. ECKEL, I.J. GOLDBERG, L. STEINER, T.J. YOST, AND J.R. PATERNITI, JR. 610

Morphological evidence for pancreatic polarity of β -cell within islets of Langerhans
S. BONNER-WEIR 616

Congenital susceptibility to NIDDM: role of intrauterine environment D.J. PETTITT, K.A. ALECK,
H.R. BAIRD, M.J. CARRAHER, P.H. BENNETT, AND W.C. KNOWLER 622

Adenine nucleotide metabolism in hearts of diabetic rats: comparison to diaphragm, liver,
and kidney R.L. JENKINS, H.G. McDANIEL, S. DIGERNESS, S.W. PARRISH, AND R.L. ONG 629

Developmental regulation of insulin and type I insulin-like growth factor receptors and
absence of type II receptors in chicken embryo tissues L. BASSAS, M.A. LESNIAK,
J. SERRANO, J. ROTH, AND F. DE PABLO 637

Binding of cytoplasmic islet cell antibodies is blocked by human pancreatic glycolipid
extracts P.G. COLMAN, R.C. NAYAK, I.L. CAMPBELL, AND G.S. EISENBARTH 645

RAPID PUBLICATIONS

Insulin resistance by uncleaved insulin proreceptor: emergence of binding site by
trypsin M. KOBAYASHI, T. SASAOKA, Y. TAKATA, A. HISATOMI, AND Y. SHIGETA 653

Characterization and expression of human HepG2/erythrocyte glucose-transporter gene
H. FUKUMOTO, S. SEINO, H. IMURA, Y. SEINO, AND G.I. BELL 657

SUPPLEMENT

International research symposium on immunology of diabetes N.K. MACLAREN, A.A. ROSSINI,
AND G.S. EISENBARTH 662

REVIEWERS OF MANUSCRIPTS



TIMING IS E



EVERYTHING



Effective control time and time again¹

Effective control of fasting and postprandial glucose—patient after patient, meal after meal, year after year.

Insulin when it's needed

Insulin levels are rapidly elevated in response to a meal, then return promptly to basal levels after the meal challenge subsides.

Timed to minimize risks

Rapidly metabolized and excreted, with an excellent safety profile.¹ As with all sulfonylureas, hypoglycemia may occur.

In concert with diet in non-insulin-dependent diabetes mellitus

Glucotrol[®]
(glipizide) 5-mg and 10-mg
Scored Tablets 

**SYNCHRONIZED
SULFONYLUREA THERAPY**

Please see brief summary of Glucotrol[®] (glipizide) prescribing information on next page.

ROERIG 
A division of Pfizer Pharmaceuticals
New York, New York 10017

Reference:

1. Sachs R, Frank M, Fishman SK: Overview of clinical experience with glipizide. In *Glipizide: A Worldwide Review*. Princeton, NJ, Excerpta Medica, 1984, pp 163-172.

GLUCOTROL® (glipizide) Tablets**Brief Summary of Prescribing Information**

INDICATIONS AND USAGE: GLUCOTROL is indicated as an adjunct to diet for the control of hyperglycemia in patients with non-insulin-dependent diabetes mellitus (NIDDM, type II) after an adequate trial of dietary therapy has proved unsatisfactory.

CONTRAINDICATIONS: GLUCOTROL is contraindicated in patients with known hypersensitivity to the drug or with diabetic ketoacidosis, with or without coma, which should be treated with insulin.

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY: The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (*Diabetes*, 19, supp. 2:747-830, 1970).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2-1/2 times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of GLUCOTROL and of alternative modes of therapy.

Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

PRECAUTIONS: Renal and Hepatic Disease: The metabolism and excretion of GLUCOTROL may be slowed in patients with impaired renal and/or hepatic function. Hypoglycemia may be prolonged in such patients should it occur.

Hypoglycemia: All sulfonylureas are capable of producing severe hypoglycemia. Proper patient selection, dosage, and instructions are important to avoid hypoglycemia. Renal or hepatic insufficiency may increase the risk of hypoglycemic reactions. Elderly, debilitated or malnourished patients and those with adrenal or pituitary insufficiency are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly or people taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used.

Loss of Control of Blood Glucose: A loss of control may occur in diabetic patients exposed to stress such as fever, trauma, infection or surgery. It may then be necessary to discontinue GLUCOTROL and administer insulin.

Laboratory Tests: Blood and urine glucose should be monitored periodically. Measurement of glycosylated hemoglobin may be useful.

Information for Patients: Patients should be informed of the potential risks and advantages of GLUCOTROL of alternative modes of therapy, as well as the importance of adhering to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure should also be explained.

Drug Interactions: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including non-steroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. *In vitro* studies indicate that GLUCOTROL binds differently than tolbutamide and does not interact with salicylate or dicumarol. However, caution must be exercised in extrapolating these findings to a clinical situation. Certain drugs tend to produce hyperglycemia and may lead to loss of control, including the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known.

Carcinogenesis, Mutagenesis, Impairment of Fertility: A 20-month study in rats and an 18-month study in mice at doses up to 75 times the maximum human dose revealed no evidence of drug-related carcinogenicity. Bacterial and *in vivo* mutagenicity tests were uniformly negative. Studies in rats of both sexes at doses up to 75 times the human dose showed no effects on fertility.

Pregnancy: Pregnancy Category C. GLUCOTROL (glipizide) was found to be mildly fetotoxic in rat reproductive studies at all dose levels (5-50 mg/kg). This fetotoxicity has been similarly noted with other sulfonylureas, such as tolbutamide and tolazamide. The effect is perinatal and believed to be directly related to the pharmacologic (hypoglycemic) action of GLUCOTROL. In studies in rats and rabbits no teratogenic effects were found. There are no adequate and well controlled studies in pregnant women. GLUCOTROL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Because recent information suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.

Nonteratogenic Effects: Prolonged severe hypoglycemia has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. This has been reported more frequently with the use of agents with prolonged half-lives. GLUCOTROL should be discontinued at least one month before the expected delivery date.

Nursing Mothers: Since some sulfonylurea drugs are known to be excreted in human milk, insulin therapy should be considered if nursing is to be continued.

Pediatric Use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: In controlled studies, the frequency of serious adverse reactions reported was very low. Of 702 patients, 11.8% reported adverse reactions and in only 1.5% was GLUCOTROL discontinued.

Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections.

Gastrointestinal: Gastrointestinal disturbances, the most common, were reported with the following approximate incidence: nausea and diarrhea, one in 70; constipation and gastralgia, one in 100. They appear to be dose-related and may disappear on division or reduction of dosage. Cholestatic jaundice may occur rarely with sulfonylureas. GLUCOTROL should be discontinued if this occurs.

Dermatologic: Allergic skin reactions including erythema, morbilliform or maculopapular eruptions, urticaria, pruritus, and eczema have been reported in about one in 70 patients. These may be transient and may disappear despite continued use of GLUCOTROL. If skin reactions persist, the drug should be discontinued. Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas.

Hematologic: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas.

Metabolic: Hepatic porphyria and disulfiram-like alcohol reactions have been reported with sulfonylureas. Clinical experience to date has shown that GLUCOTROL has an extremely low incidence of disulfiram-like reactions.

Endocrine Reactions: Cases of hyponatremia and the syndrome of inappropriate antidiuretic hormone (SIADH) secretion have been reported with this and other sulfonylureas.

Miscellaneous: Dizziness, drowsiness, and headache have been reported in about one in fifty patients treated with GLUCOTROL. They are usually transient and seldom require discontinuance of therapy.

OVERDOSAGE: Overdosage of sulfonylureas including GLUCOTROL can produce hypoglycemia. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours since hypoglycemia may recur after apparent clinical recovery. Clearance of GLUCOTROL from plasma would be prolonged in persons with liver disease. Because of the extensive protein binding of GLUCOTROL (glipizide), dialysis is unlikely to be of benefit.

DOSAGE AND ADMINISTRATION: There is no fixed dosage regimen for the management of diabetes mellitus with GLUCOTROL. In general, it should be given approximately 30 minutes before a meal to achieve the greatest reduction in postprandial hyperglycemia.

Initial Dose: The recommended starting dose is 5 mg before breakfast. Geriatric patients or those with liver disease may be started on 2.5 mg. Dosage adjustments should ordinarily be in increments of 2.5-5 mg, as determined by blood glucose response. At least several days should elapse between titration steps.

Maximum Dose: The maximum recommended total daily dose is 40 mg.

Maintenance: Some patients may be effectively controlled on a once-a-day regimen, while others show better response with divided dosing. Total daily doses above 15 mg should ordinarily be divided.

HOW SUPPLIED: GLUCOTROL is available as white, dye-free, scored diamond-shaped tablets imprinted as follows: 5 mg tablet—Pfizer 411 (NDC 5 mg 0049-4110-66) Bottles of 100; 10 mg tablet—Pfizer 412 (NDC 10 mg 0049-4120-65) Bottles of 100.

CAUTION: Federal law prohibits dispensing without prescription.

More detailed professional information available on request.

MAY AUTHOR INDEX

(Volume 37, Number 5)

- Agharanya, J.C., 540
 Albisser, A.M., 526
 Aleck, K.A., 622
 Ashford, M.L.J., 495
- Baird, H.R., 622
 Bassas, L., 637
 Bell, G.I., 657
 Bending, J.J., 507
 Bennett, P.H., 622
 Bonner-Weir, S., 616
 Burant, C.F., 499
 Buse, M.G., 499
- Campbell, I.L., 645
 Carraher, M.J., 622
 Cohen, M.P., 558
 Colman, P.G., 645
 Cook, D.L., 495
 Corsetti, L., 569
- De Pablo, F., 637
 Digerness, S., 629
- Eckel, R.H., 610
 Eisenbarth, G.S., 645, 662
 Elbein, S.C., 569
- Favreau, L.V., 577
 Fukumoto, H., 657
 Furcht, L.T., 532
- Garvey, W.T., 590
 Gerich, J.E., 512
 Goldberg, I.J., 610
 Goldgar, D., 569
 Greiner, D.L., 520
 Gulan, M., 526
- Hales, C.N., 495
 Handler, E.S., 520
 Hammond, M.W., 512
 Helderman, J.H., 600
 Heyner, S., 585
 Hisatomi, A., 653
- Imamura, T., 600
 Imura, H., 657
 Inman, L., 600
- Jenkins, R.L., 629
- Klass, D., 544
 Klein, R.L., 550
 Klepser, H., 558
 Knowler, W.C., 622
 Knowles, B.B., 563
 Kobayashi, M., 653
 Koffler, M., 600
 Koltman, O.G., 590
- Lesniak, M.A., 637
 Lobo-Yeo, A., 507
 Lopes-Virella, M.F., 550
 Lyons, T.J., 550
- Maclaren, N.K., 662
 Matschinsky, F.M., 563
 Mattson, B.A., 585
 McDaniel, H.G., 629
 Mordes, J.P., 520
- Naimark, D., 544
 Nakano, K., 520
 Nayak, R.C., 645
 Nissen, S.L., 512
- O'Neill, S.J., 544
 Olefsky, J.M., 590
 Ong, R.L., 629
- Parrish, S.W., 629
 Paterniti, J.R., Jr., 610
 Pehling, G., 512
 Perlman, K., 526
 Permutt, M.A., 569
 Pettitt, D.J., 622
 Prince, D., 600
- Reger, L.A., 532
 Rizza, R.A., 512
 Rosenblum, I.Y., 585
 Rossini, A.A., 520, 662
 Roth, J., 637
 Rubenstein, A.H., 590
- Sasaoka, T., 653
 Satin, L.S., 495
 Schenkman, J.B., 577
 Seino, S., 657
 Seino, Y., 657
 Serrano, J., 637
 Service, F.J., 512
 Shiget, Y., 653
 Shimizu, T., 563
 Sima, A.A.F., 544
 Skolnick, M., 569
 Smith, R.M., 585
 Sole, M., 526
 Sowell, M.O., 499
 Steiner, L., 610
 Stevenson, H.C., 550
- Takata, Y., 653
 Tarsio, J.F., 532
 Tessari, P., 512
 Thirlby, R., 600
 Treutelaar, M.K., 499
- Unger, R.H., 600
- Vergani, D., 507
 Viberti, G.C., 507
- Witztum, J.L., 550
- Yagihashi, S., 544
 Yost, T.J., 610
- Zinman, B., 526

Editor

R. PAUL ROBERTSON, MD

Associate Editors

ROBERT P. ELDE, PhD

FRANK Q. NUTTALL, MD, PhD

STEPHEN RICH, PhD

ROBERT L. SORENSON, PhD

MICHAEL W. STEFFES, MD, PhD

Editorial Assistant

LUCILLE MARIE SHRADER

Editorial Board

LLOYD AXELROD, MD

RICHARD BERGMAN, MD

AUBREY E. BOYD III, MD

WILLIAM CHICK, MD

WILLIAM DUCKWORTH, MD

DARYL GRANNER, MD

GEROLD M. GRODSKY, MD

JEFFREY B. HALTER, MD

EDWARD HORTON, MD

LEONARD JARETT, MD

TETSURO KONO, PhD

ÅKE LERNMARK, MD

ERROL MARLISS, MD

MICHAEL McDANIEL, PhD

STEWART A. METZ, MD

DANIEL H. MINTZ, MD

STEPHEN POHL, MD

BARRY I. POSNER, MD

ALDO ROSSINI, MD

ROBERT SHERWIN, MD

MICHAEL P. STERN, MD

DAVID SUTHERLAND, MD

GORDON WEIR, MD

Publisher

CAROLINE STEVENS

Director of Professional Publications

BEVERLY BRITTAN COOK

Managing Editor

ORIT LOWY CHICHERIO

Assistant Managing Editor

DEMARIE JACKSON

Assistant Editors

PAMELA HARLEY-KARL

ANNE WILSON

Publications Assistant

YOLANDA CHRISTIE WALTERS

Advertising Coordinator

PEGGY B. DONOVAN

American Diabetes Association

Officers 1987-88

Chairman of the Board

S. DOUGLAS DODD

President

JOHN A. COLWELL, MD, PhD

Chairman of the Board-Elect

WILLIAM A. MAMRACK

President-Elect

CHARLES CLARK, JR., MD

Senior Vice-President

LINDA S. HURWITZ, RN, MS

Vice-Chairman of the Board

STERLING TUCKER

Vice-Presidents

SHERMAN M. HOLVEY, MD

ALAN D. CHERRINGTON, PhD

Secretary

GLORIA HIRSCH

Treasurer

GORDON R. MARDIS

Executive Vice-President

ROBERT S. BOLAN

diabetes

A JOURNAL OF THE AMERICAN DIABETES ASSOCIATION.

Diabetes and *Diabetes Care* are scientific research journals published by the American Diabetes Association. Both publish original high-quality reports on biomedical research related to the broad field of diabetes mellitus.

Diabetes does not publish material that has been reported elsewhere. In submitting an article the author(s) must state in the covering letter that the material has not been published elsewhere and has not been submitted for publication elsewhere. Prior publication specifically includes symposia, proceedings, preliminary communications, books, and invited articles. It is assumed that all human investigation shall have been conducted according to the principles expressed in the Declaration of Helsinki. Accepted manuscripts incur a charge of \$25 per printed page.

For studies involving experimental animals, state the species, strain, number used, and other pertinent descriptive characteristics. For human subjects or patients, describe their characteristics. When describing surgical procedures on animals, identify the preanesthetic and anesthetic agents used, and state the amount or concentration and the route and frequency of administration for each. The use of paralytic agents, such as curare or succinylcholine, is not an acceptable substitute for anesthetics. For other invasive procedures on animals, report the analgesic or tranquilizing drugs used; if none was used, provide justification for such exclusion. When reporting studies on unanesthetized animals or on humans, indicate that the procedures followed were in accordance with institutional guidelines.

In view of *The Copyright Revision Act of 1976*, all transmittal letters to the editor must contain the following language before manuscripts can be reviewed for possible publication: "In consideration of ADA's reviewing and editing of my (our) submission, the author(s) undersigned hereby transfers, assigns, or otherwise conveys all copyright ownership to the ADA in the event that such work is published by the ADA." We regret that transmittal letters not containing the foregoing language signed by all authors of the manuscript will necessitate return of your manuscript.

Matter appearing in *Diabetes* is copyrighted by the American Diabetes Association, Inc. Permission to reproduce all or parts of papers appearing in it may be granted under appropriate conditions and if proper credit is given. Such requests should be addressed in writing to the Permissions Editor, accompanied by a letter of permission from the senior author.

All signed articles and editorials are the responsibility of the author(s) and not that of the American

Diabetes Association. The Editors will be pleased to consider for publication papers presented at the Annual Meeting of the association.

Rapid Publications: Observations considered to be of unusual importance may be submitted as a Rapid Publication. Editorial decision will be made within 10 days after receipt of the manuscript. No written review or explanation of the decision will be provided. Rejected papers may be resubmitted as a regular manuscript and reviewed accordingly. Rapid Publications may not exceed 10 double-spaced typewritten pages (including figures, tables, and references). Accepted papers will be published in the earliest possible issue of the Journal.

Manuscripts should be typewritten (not photocopied), with double-spacing; submit original and 2 photocopies with 2 prints of figures and photomicrographs. Manuscripts prepared in accord with the requirements specified in the document "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," *Annals of Internal Medicine* 96:766-71, 1982, will be considered for publication.

References should be presented in the style of the following examples and numbered in order of appearance in the text: For Periodicals—Banting FG, Best CH: The internal secretion of the pancreas. *J Lab Clin Med* 7:251-66, 1922. For Books—Allen M: *Studies Concerning Glycosuria and Diabetes*. Cambridge, MA, Harvard Univ. Press, 1913, p. 461.

A summary of the content of the paper of not more than 250 words should be provided. This should be self-contained and understandable without reference to the text.

Photographs, drawings, and figures should be suitable for reproduction. Photographs should be unmounted, untrimmed glossy prints. The names of authors should appear on the back. The tops of photographs and figures should be indicated.

Galley proofs are sent to the principal author with a price list and order blank for reprints.

All manuscripts and related correspondence should be sent by 1st class mail addressed to R. Paul Robertson, M.D., University of Minnesota, P.O. Box 731, Minneapolis, MN 55440-0731. Express mail or correspondence requiring street address should be addressed to R. Paul Robertson, M.D., Phillips-Wangensteen Bldg., Rm. 6-124, 516 Delaware St. SE, Minneapolis, MN 55455. Editorial correspondence should be addressed to the Editorial Office, *Diabetes*, American Diabetes Association, Inc., National Service Center, 1660 Duke Street, Alexandria, Virginia 22314.

Diabetes (ISSN 0012-1797) is published monthly by the American Diabetes Association, Inc., 1660 Duke Street, Alexandria, Virginia 22314. Professional membership dues include \$70 designated for *Diabetes*. Subscription rates for nonmembers: \$70 for 1 year/\$125 for 2 years in the United States and Canada; \$105 for 1 year/\$195 for 2 years in all other countries. Individual copies: \$8 in the United States and Canada; \$12 in all other countries. Second-class postage paid at Alexandria, Virginia 22314, and at additional mailing offices. POSTMASTER: Send change of address to *Diabetes*, American Diabetes Association, P.O. Box 2055, Harlan, IA 51593-0238.

Subscription correspondence should be addressed to *Diabetes*, Subscription Department, P.O. Box 2055, Harlan, IA 51593-0238. Checks, money orders, and drafts for subscriptions should be made payable to the American Diabetes Association, Inc., and must accompany subscription orders. For more information call toll free 1-800-ADA-DISC 8:30 a.m. to 5:00 p.m., E.T., Monday through Friday. In Alaska, Hawaii, Virginia, and outside of the U.S., call 703-549-1500.

Advertising inquiries should be addressed to Peggy Donovan, Advertising Coordinator, American Diabetes Association, 1660 Duke St., Alexandria, VA 22314. Tel.: (703) 549-1500.

TRACER™

Blood Glucose Micro-monitor

UNMISTAKABLY THE ONE FOR PATIENTS ON THE GO

Ideal for accurate results anywhere, anytime

Considering today's hectic lifestyles, it's important that your diabetes patients be able to test for their blood glucose easily in settings other than the home. That's why Boehringer Mannheim Diagnostics has designed the TRACER™ Blood Glucose Micro-monitor for patients on the go.

Since it fits so easily into pocket or purse, your patients can test conveniently anywhere, anytime. And you can count on TRACER™ for accurate and reliable blood glucose readings in the 40 to 400 mg/dL range.


Special features for extra convenience

TRACER™ has other advantages as well, such as the unique TRACER bG™ Test Strips which are smaller than conventional strips and thus require less blood. In addition, these strips utilize the same superior chemistry as CHEMSTRIP bG® Test Strips. Furthermore, TRACER™ has a convenient memory function that allows for storage of up to seven glucose values so that your patients can test now and record their results later.


High quality to meet the highest standards

TRACER™ has been developed to meet the highest standards of quality, accuracy and convenience. At Boehringer Mannheim Diagnostics, the commitment to achieve better diabetes control through technology and education is ongoing.

For more information, please contact your Boehringer Mannheim Diagnostics sales representative or call toll-free 1-800-858-8072.



**THE LINE OF CONFIDENCE™
IN DIABETES CONTROL**



© 1987 Boehringer Mannheim Corporation. All rights reserved.

**BOEHRINGER
MANNHEIM**
DIAGNOSTICS

9115 Hague Road
PO Box 50100
Indianapolis, IN 46250



DIABETES FORECAST EDITOR

The American Diabetes Association invites applications for the editorship of *Diabetes Forecast*, the Association's monthly magazine for people with diabetes and their families.

The appointment is for three years. Interested parties should submit a letter of intent by June 15, 1988. A curriculum vitae should be included. Further instructions will follow upon receipt of the letter of intent.

Please address correspondence to: Pasquale J. Palumbo, M.D.
American Diabetes Association
1660 Duke Street
Alexandria, VA 22314
Attention: Susan Coughlin



Joslin Diabetes Center

The Action of Insulin and Related Growth Factors in Diabetes Mellitus

October 10-13, 1988 in Boston, Massachusetts

An international symposium held in conjunction with Harvard Medical School to
celebrate Joslin's 90th Anniversary

Topics include:

Alterations in Insulin Action in Diabetes
Insulin Receptor: Structure, Function and
Regulation
Signal Transduction Systems
Cellular Actions of Insulin
Growth Factor Receptors and Receptor
Cycling

Abstract and Poster Presentations

Scientific Secretaries:

C. Ronald Kahn, M.D.
Robert J. Smith, M.D.


For registration and abstract forms, contact:

Mr. James Evans, Research Division,
Joslin Diabetes Center, One Joslin Place,
Boston, MA 02215 (617) 732-2472

Sponsored by the Iacocca Foundation

Travel grants by Upjohn Pharmaceuticals

NEW FEATURES...




ADDED CAPABILITIES

COBAS MIRA incorporates exciting new features you've been waiting for. Along with the reliability and efficiency you've come to expect for STAT and routine assays, you get added capabilities.

Our new reagent racks provide simultaneous, convenient, random access testing for TDMs and thyroids, in addition to isoenzymes, general chemistries and electrolytes. Our sophisticated new software design combines

unmatched flexibility with unprecedented simplicity. And new Syva Emit® Convenience Packs, specially configured for the COBAS MIRA, slash reagent handling time for immunoassays.

Whether you need a complete, self-contained chemistry system or a dedicated TDM/specialty analyzer, choose COBAS MIRA — the army of one. For more information and added capabilities, call 1-800-526-1247.



COBAS MIRA™
THE ARMY OF ONE

COBAS MIRA is a trademark of Roche Diagnostic Systems, Inc., Montclair, NJ 07042.



Roche Diagnostic Systems

a subsidiary of Hoffmann-La Roche Inc.


Roche Diagnostic Systems, Inc.
 One Sunset Avenue
 Montclair, New Jersey 07042-5199

Emit is a registered trademark of the Syva Company, Palo Alto, CA 94304.

Pathway to progress in



controlling the complications of diabetes



Our international researchers first brought beta blockade to the medical community...then topped that achievement with TENORMIN® (atenolol), the world's leading beta blocker.

The same expertise developed NOLVADEX® (tamoxifen citrate), the first antiestrogen therapy. It also created HIBICLENS® (chlorhexidine gluconate), the most widely used

hospital antiseptic/antimicrobial skin cleanser. And it is contributing major advances in anesthesiology and the treatment of infectious disease, across the United States and abroad.

Now the world-renowned research expertise of Stuart Pharmaceuticals and ICI Pharma is tackling the challenge of the complications of diabetes.

Together, as companies of the ICI Pharmaceuticals Group, we are deeply committed to ongoing clinical research in this vital field. As with our past achievements, each step of our exploration involves thousands of research hours and is aimed toward meeting your needs and the needs of your patients.

Following this pathway, we look forward to a day in which the promise of this intensive effort becomes a clinical reality.

Committed to improving the control of diabetic complications



STUART PHARMACEUTICALS

Division of ICI Americas Inc.
Wilmington, Delaware 19897



ICI PHARMA


Division of ICI Americas Inc.
WILMINGTON, DELAWARE 19897 USA

FINAL REPORT

The Working Group on Hypertension in Diabetes:

CAPOTEN[®] (captopril tablets)
FIRST-LINE THERAPY
FOR HYPERTENSIVE DIABETIC
PATIENTS*

HYPERTENSION
IN DIABETES



Final Report of the Working
Group on Hypertension
in Diabetes

Approved by the
National High Blood Pressure
Education Program
Coordinating Committee on
January 16, 1987

A National High Blood Pressure
Education Program

Controls hypertension today

CAPOTEN controls blood pressure without altering insulin secretion or complicating diabetes management.^{1,2}

Offers potential long-term benefits

CAPOTEN does not deplete potassium or alter lipid levels.

THE CAPOTEN[®] (captopril tablets) DIFFERENCE



*CAPOTEN may be used as initial therapy only for patients with normal renal function in whom the risk of neutropenia/agranulocytosis is relatively low (1 out of over 8,600 in clinical trials). Use special precautions in patients with impaired renal function, collagen vascular disorders, or those exposed to other drugs known to affect the white cells or immune response. Evaluation of hypertensives should always include assessment of renal function. See INDICATIONS AND USAGE, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS in the brief summary on the adjacent page.

References:

1. The Working Group on Hypertension in Diabetes: Statement on Hypertension in Diabetes Mellitus: Final Report. Arch Intern Med 147:830-842, 1987.
2. D'Angelo A, Sartori L, Gambaro G, et al: Captopril in the treatment of hypertension in type I and type II diabetic patients. Postgrad Med J 62(suppl 1):69-72, 1986.

THE CAPOTEN[®] (captopril tablets) DIFFERENCE

CAPOTEN[®] TABLETS

Captopril Tablets

INDICATIONS: Hypertension—CAPOTEN (captopril) is indicated for the treatment of hypertension. Consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS). CAPOTEN may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for those who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. CAPOTEN is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics.

Heart Failure: CAPOTEN (captopril) is indicated in patients with heart failure who have not responded adequately to or cannot be controlled by conventional diuretic and digitalis therapy. CAPOTEN is to be used with diuretics and digitalis.

CONTRAINDICATIONS: CAPOTEN is contraindicated in patients who are hypersensitive to this product.

WARNINGS: Neutropenia/Agranulocytosis—Neutropenia (<1000/mm³) with myeloid hypoplasia has resulted from use of captopril. About half of the neutropenic patients developed systemic or oral cavity infections or other features of the syndrome of agranulocytosis. The risk of neutropenia is dependent on the clinical status of the patient:

In clinical trials in patients with hypertension who have normal renal function (serum creatinine less than 1.6 mg/dL and no collagen vascular disease), neutropenia has been seen in one patient out of over 8,600 exposed. In patients with some degree of renal failure (serum creatinine at least 1.6 mg/dL) but no collagen vascular disease, the risk in clinical trials was about 1 per 500. Doses were relatively high in these patients, particularly in view of their diminished renal function. In patients with collagen vascular diseases (e.g., systemic lupus erythematosus, scleroderma) and impaired renal function, neutropenia occurred in 3.7% of patients in clinical trials. While none of the over 750 patients in formal clinical trials of heart failure developed neutropenia, it has occurred during the subsequent clinical experience. Of reported cases, about half had serum creatinine \geq 1.6 mg/dL and more than 75% received procainamide. In heart failure, it appears that the same risk factors for neutropenia are present.

Neutropenia has appeared usually within 3 months after starting therapy, associated with myeloid hypoplasia and frequently accompanied by erythroid hypoplasia and decreased numbers of megakaryocytes (e.g., hypoplastic bone marrow and pancytopenia); anemia and thrombocytopenia were sometimes seen. Neutrophils generally returned to normal in about 2 weeks after captopril was discontinued, and serious infections were limited to clinically complex patients. About 13% of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. **Evaluation of the hypertensive or heart failure patient should always include assessment of renal function.** If captopril is used in patients with impaired renal function, white blood cell and differential counts should be evaluated prior to starting treatment and at approximately 2-week intervals for about 3 months, then periodically. In patients with collagen vascular disease or who are exposed to other drugs known to affect the white cells or immune response, particularly when there is impaired renal function, captopril should be used only after an assessment of benefit and risk, and then with caution. All patients treated with captopril should be told to report any signs of infection (e.g., sore throat, fever). If infection is suspected, perform white cell counts without delay. Since discontinuation of captopril and other drugs has generally led to prompt return of the white count to normal, upon confirmation of neutropenia (neutrophil count <1000/mm³) withdraw captopril and closely follow the patient's course.

Proteinuria: Total urinary proteins $>$ 1 g per day were seen in about 0.7% of patients on captopril. About 90% of affected patients had evidence of prior renal disease or received high doses (>150 mg/day), or both. The nephrotic syndrome occurred in about one-fifth of proteinuric patients. In most cases, proteinuria subsided or cleared within 6 months whether or not captopril was continued. The BUN and creatinine were seldom altered in proteinuric patients. Since most cases of proteinuria occurred by the 8th month of therapy with captopril, patients with prior renal disease or those receiving captopril at doses $>$ 150 mg per day, should have urinary protein estimates (dip-stick on 1st morning urine) before therapy, and periodically thereafter.

Hypotension: Excessive hypotension was rarely seen in hypertensive patients but is a possibility in severely salt/volume-depleted persons such as those treated vigorously with diuretics (see PRECAUTIONS [Drug Interactions]). In heart failure, where the blood pressure was either normal or low, transient decreases in mean blood pressure $>$ 20% were recorded in about half of the patients. This transient hypotension may occur after any of the first several doses and is usually well tolerated, although rarely it has been associated with arrhythmia or conduction defects. A starting dose of 6.25 or 12.5 mg tid may minimize the hypotensive effect. Patients should be followed closely for the first 2 weeks of treatment and whenever the dose of captopril and/or diuretic is increased.

BECAUSE OF THE POTENTIAL FALL IN BLOOD PRESSURE IN THESE PATIENTS, THERAPY SHOULD BE STARTED UNDER VERY CLOSE MEDICAL SUPERVISION.

PRECAUTIONS: General: Impaired Renal Function—Hypertension—Some hypertensive patients with renal disease, particularly those with severe renal artery stenosis, have developed increases in BUN and serum creatinine. It may be necessary to reduce captopril dosage and/or discontinue diuretic. For some of these patients, normalization of blood pressure and maintenance of adequate renal perfusion may not be possible.

Heart Failure—About 20% of patients develop stable elevations of BUN and serum creatinine $>$ 20% above normal or baseline upon long-term treatment. Less than 5% of patients, generally with severe preexisting renal disease, required discontinuation due to progressively increasing creatinine. See DOSAGE AND ADMINISTRATION, ADVERSE REACTIONS [Altered Laboratory Findings]. **Valvular Stenosis**—A theoretical concern, for risk of decreased coronary perfusion, has been noted regarding vasodilator treatment in patients with aortic stenosis due to decreased afterload reduction. **Surgery/Anesthesia**—If hypotension occurs during surgery or anesthesia, and is considered due to the effects of captopril, it is correctable by volume expansion.

Drug Interactions: Hypotension—Patients on Diuretic Therapy—Precipitous reduction of blood pressure may occasionally occur within the 1st hour after administration of the initial of captopril dose in patients on diuretics, especially those recently placed on diuretics, and those on severe dietary salt restriction or dialysis. This possibility can be minimized

by either discontinuing the diuretic or increasing the salt intake about 1 week prior to initiation of captopril therapy or by initiating therapy with small doses (6.25 or 12.5 mg). Alternatively, provide medical supervision for at least 1 hour after the initial dose.

Agents Having Vasodilator Activity—In heart failure patients, vasodilators should be administered with caution.

Agents Causing Renin Release—Captopril's effect will be augmented by antihypertensive agents that cause renin release.

Agents Affecting Sympathetic Activity—The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril alone or with diuretics. Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive. Therefore, use agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) with caution.

Agents Increasing Serum Potassium—Give potassium-sparing diuretics or potassium supplements only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. Use potassium-containing salt substitutes with caution.

Inhibitors of Endogenous Prostaglandin Synthesis—Indomethacin and other nonsteroidal anti-inflammatory agents may reduce the antihypertensive effect of captopril, especially in low renin hypertension.

Drug/Laboratory Test Interaction: Captopril may cause a false-positive urine test for acetone.

Carcinogenesis, Mutagenesis and Impairment of Fertility: Two-year studies with doses of 50 to 1350 mg/kg/day in mice and rats failed to show any evidence of carcinogenic potential. Studies in rats have revealed no impairment of fertility.

Pregnancy: Category C: There are no adequate and well-controlled studies in pregnant women. Embryocidal effects and craniofacial malformations were observed in rabbits. Therefore, captopril should be used during pregnancy, or for patients likely to become pregnant, only if the potential benefit outweighs the potential risk to the fetus. Captopril crosses the human placenta.

Nursing Mothers: Captopril is secreted in human milk. Exercise caution when administering captopril to a nursing woman, and, in general, nursing should be interrupted.

Pediatric Use: Safety and effectiveness in children have not been established although there is limited experience with use of captopril in children from 2 months to 15 years of age. Dosage, on a weight basis, was comparable to that used in adults. CAPOTEN (captopril) should be used in children only if other measures for controlling blood pressure have not been effective.

ADVERSE REACTIONS: Reported incidences are based on clinical trials involving approximately 7000 patients.

Renal—About 1 of 100 patients developed proteinuria (see WARNINGS). Renal insufficiency, renal failure, polyuria, oliguria, and urinary frequency in 1 to 2 of 1000 patients.

Hematologic—Neutropenia/agranulocytosis has occurred (see WARNINGS). Anemia, thrombocytopenia, and pancytopenia have been reported.

Dermatologic—Rash, (usually maculopapular, rarely urticarial), often with pruritus, and sometimes with fever and eosinophilia, in about 4 to 7 of 100 patients (depending on renal status and dose), usually during the 1st 4 weeks of therapy. Pruritus, without rash, in about 2 of 100 patients. A reversible associated pemphigoid-like lesion, and photosensitivity, have also been reported. Angioedema of the face, mucous membranes of the mouth, or of the extremities in about 1 of 1000 patients—reversible on discontinuance of captopril therapy. One case of laryngeal edema has been reported. Flushing or pallor in 2 to 5 of 1000 patients.

Cardiovascular—Hypotension may occur; see WARNINGS and PRECAUTIONS [Drug Interactions] for discussion of hypotension on initiation of captopril therapy. Tachycardia, chest pain, and palpitations each in about 1 of 100 patients. Angina pectoris, myocardial infarction, Raynaud's syndrome, and congestive heart failure each in 2 to 3 of 1000 patients.

Dysgeusia—Approximately 2 to 4 (depending on renal status and dose) of 100 patients developed a diminution or loss of taste perception; taste impairment is reversible and usually self-limited even with continued drug use (2 to 3 months). Gastric irritation, abdominal pain, nausea, vomiting, diarrhea, anorexia, constipation, aphthous ulcers, peptic ulcer, dizziness, headache, malaise, fatigue, insomnia, dry mouth, dyspnea, cough, alopecia, paresthesias reported in about 0.5 to 2% of patients but did not appear at increased frequency compared to placebo or other treatments used in controlled trials.

Altered Laboratory Findings: Elevations of liver enzymes in a few patients although no causal relationship has been established. Rarely cholestatic jaundice, and hepatocellular injury with or without secondary cholestasis, have been reported. A transient elevation of BUN and serum creatinine may occur, especially in volume-depleted or renovascular hypertension patients. In instances of rapid reduction of longstanding or severely elevated blood pressure, the glomerular filtration rate may decrease transiently, also resulting in transient rises in serum creatinine and BUN. Small increases in serum potassium concentration frequently occur, especially in patients with renal impairment (see PRECAUTIONS).

OVERDOSAGE: Primary concern is correction of hypotension. Volume expansion with an I.V. infusion of normal saline is the treatment of choice for restoration of blood pressure. Captopril may be removed from the general circulation by hemodialysis.

DOSAGE AND ADMINISTRATION: CAPOTEN (captopril) should be taken one hour before meals. In hypertension, CAPOTEN may be dosed bid or tid. Dosage must be individualized; see DOSAGE AND ADMINISTRATION section of package insert for detailed information regarding dosage in hypertension and in heart failure. Because CAPOTEN (captopril) is excreted primarily by the kidneys, dosage adjustments are recommended for patients with impaired renal function.

Consult package insert before prescribing CAPOTEN (captopril).

HOW SUPPLIED: Available in tablets of 12.5, 25, and 50 mg in bottles of 100 and 1000; 100 mg in bottles of 100; and in UNIMATIC[®] unit-dose packs of 100 tablets. (J3-658K)





Unequalled injection comfort delivers unequalled patient compliance.

B-D *delivers.*

B-D MICRO-FINE® III is the thinnest, finest, sharpest needle ever made—for unequalled injection comfort.

The result is unequalled patient compliance with your insulin-administration instructions. No wonder physicians, nurses and hospitals use B-D syringes more than all other brands combined.



Your patients will find a money-back guarantee on every box of B-D syringes. It is our assurance to them of receiving the most comfortable injections they've ever had.

For diabetics with peripheral arterial disease...




Circulatory insufficiency—a well-known factor in the pathogenesis of diabetic complications—predisposes diabetics to intermittent claudication.¹ In addition to narrowing of the blood vessels, two specific microcirculatory abnormalities—decreased red cell flexibility and increased blood viscosity—are also associated with diabetes.^{1,2} Although ideal glucose control might correct these abnormalities, glucose levels do fluctuate, and patients remain at risk.



when microcirculatory blood flow improves, so does life.



Though glucose control may be imperfect, Trental® increases red cell flexibility and lowers blood viscosity. The flow of red cells—which are larger than the diameter of the microcirculatory vessels—is enhanced through the capillary bed, and tissue perfusion and oxygenation improve.³⁻⁵



Evidence of improved perfusion and oxygenation has been obtained from experimental measurements of partial pressures of oxygen (pO_2) in the calf muscles of patients with limb ischemia given Trental®.⁶

Significant improvement in stabilized diabetics²


The effectiveness of Trental® on intermittent claudication has been demonstrated in a controlled trial of 50 maturity-onset diabetics stabilized on insulin, oral antidiabetics, or diet alone. Eighty-four percent of patients receiving Trental® 400 mg b.i.d. showed a significant improvement in walking distance, compared with 17% of those on placebo.

Trental®-treated patients also had significant improvement in paresthesias, skin temperature, and subjective overall response.

Not a vasodilator • Not an anticoagulant
Not related to aspirin or dipyridamole

Trental®

(pentoxifylline) 400 mg
Tablets



**The only proven-
effective agent for
intermittent claudication
symptomatic of peripheral
arterial disease**

Trental® can improve function and symptoms, but is not intended to replace more definitive therapy such as surgery.

Please see following page for references and brief summary of prescribing information.

©1987 by Hoechst-Roussel Pharmaceuticals Incorporated.

References: 1. Oughton J, et al: Diabetes mellitus: Its effect on the flow properties of blood. *Horm Metab Res* 11 (Suppl): 112-129, 1981. 2. Schubotz R: Double-blind trial of pentoxifylline in diabetes with peripheral vascular disorders. *Pharmatherapeutica* 1(3): 172-179, 1976. 3. Dormandy JA, et al: Clinical, hemodynamic, rheological, and biochemical findings in 126 patients with intermittent claudication. *Br Med J* 4: 576, 1973. 4. Reid HL, et al: Impaired red cell deformability in peripheral vascular disease. *Lancet* 1: 666, 1967. 5. Stormer B, et al: Rheological changes in the blood of patients with chronic arterial occlusive disease after the administration of vasoactive drugs. *Curr Med Res Opin* 4: 588, 1977. 6. Ehly AM: Effects of orally administered pentoxifylline on muscular oxygen pressure in patients with intermittent claudication. *IRCS Med Sci* 10: 401, 1982.

Trental® (pentoxifylline) Tablets, 400 mg

A brief summary of the Prescribing Information follows.

INDICATIONS AND USAGE:

Trental® (pentoxifylline) is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Trental® (pentoxifylline) can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease.

CONTRAINDICATIONS:

Trental® (pentoxifylline) should not be used in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.

PRECAUTIONS:

General: Patients with chronic occlusive arterial disease of the limbs frequently show other manifestations of arteriosclerotic disease. Trental® (pentoxifylline) has been used safely for treatment of peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, but there have been occasional reports of angina, hypotension, and arrhythmia. Controlled trials do not show that Trental® (pentoxifylline) causes such adverse effects more often than placebo, but, as it is a methylxanthine derivative, it is possible some individuals will experience such responses.

Drug Interactions: Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Trental® (pentoxifylline) with and without anticoagulants or platelet aggregation inhibitors. Patients on warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examinations for bleeding including hematocrit and/or hemoglobin. Trental® (pentoxifylline) has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. Small decreases in blood pressure have been observed in some patients treated with Trental® (pentoxifylline); periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. If indicated, dosage of the antihypertensive agents should be reduced.

Carcinogenesis, Mutagenesis and Impairment of Fertility: Long-term studies of the carcinogenic potential of pentoxifylline were conducted in mice and rats by dietary administration of the drug at doses up to approximately 24 times (570 mg/kg) the maximum recommended human daily dose (MRHD) of 24 mg/kg for 18 months in mice and 18 months in rats with an additional 6 months without drug exposure in the latter. No carcinogenic potential for pentoxifylline was noted in the mouse study. In the rat study, there was a statistically significant increase in benign mammary fibroadenomas in females in the high dose group (24 X MRHD). The relevance of this finding to human use is uncertain since this was only a marginal statistically significant increase for a tumor that is common in aged rats. Pentoxifylline was devoid of mutagenic activity in various strains of *Salmonella* (Ames test) when tested in the presence and absence of metabolic activation.

Pregnancy: Category C. Teratogenic studies have been performed in rats and rabbits at oral doses up to about 25 and 10 times the maximum recommended human daily dose (MRHD) of 24 mg/kg, respectively. No evidence of fetal malformation was observed. Increased resorption was seen in rats at 25 times MRHD. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Trental® (pentoxifylline) should be used during pregnancy only if clearly needed.

Nursing Mothers: Pentoxifylline and its metabolites are excreted in human milk. Because of the potential for tumorigenicity shown for pentoxifylline in rats, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use: Safety and effectiveness in children below the age of 18 years have not been established.

ADVERSE REACTIONS:

Clinical trials were conducted using either controlled-release Trental® (pentoxifylline) tablets for up to 60 weeks or immediate-release Trental® (pentoxifylline) capsules for up to 24 weeks. Dosage ranges in the tablet studies were 400 mg bid to tid and in the capsule studies, 200-400 mg tid.

The table summarizes the incidence (in percent) of adverse reactions considered drug related, as well as the numbers of patients who received controlled-

release Trental® (pentoxifylline) tablets, immediate-release Trental® (pentoxifylline) capsules, or the corresponding placebos. The incidence of adverse reactions was higher in the capsule studies (where dose related increases were seen in digestive and nervous system side effects) than in the tablet studies. Studies with the capsule include domestic experience, whereas studies with the controlled-release tablets were conducted outside the U.S. The table indicates that in the tablet studies few patients discontinued because of adverse effects.

INCIDENCE (%) OF SIDE EFFECTS

	Controlled-Release Tablets		Immediate-Release Capsules	
	Trental®	Placebo	Trental®	Placebo
(Numbers of Patients at Risk)	(321)	(128)	(177)	(138)
Discontinued for Side Effect	3.1	0	9.6	7.2
CARDIOVASCULAR SYSTEM				
Angina/Chest Pain	0.3	—	1.1	2.2
Arrhythmia/Palpitation	—	—	1.7	0.7
Flushing	—	—	2.3	0.7
DIGESTIVE SYSTEM				
Abdominal Discomfort	—	—	4.0	1.4
Belching/Flatus/Bloating	0.6	—	9.0	3.6
Diarrhea	—	—	3.4	2.9
Dyspepsia	2.8	4.7	9.6	2.9
Nausea	2.2	0.8	28.8	8.7
Vomiting	1.2	—	4.5	0.7
NERVOUS SYSTEM				
Agitation/Nervousness	—	—	1.7	0.7
Dizziness	1.9	3.1	11.9	4.3
Drowsiness	—	—	1.1	5.8
Headache	1.2	1.6	6.2	5.8
Insomnia	—	—	2.3	2.2
Tremor	0.3	0.8	—	—
Blurred Vision	—	—	2.3	1.4

Trental® (pentoxifylline) has been marketed in Europe and elsewhere since 1972. In addition to the above symptoms, the following have been reported spontaneously since marketing, or occurred in other clinical trials with an incidence of less than 1%: the causal relationship was uncertain: Cardiovascular—dyspnea, edema, hypotension; Digestive—anorexia, cholecystitis, constipation, dry mouth/thirst; Nervous—anxiety, confusion; Respiratory—epistaxis, flu-like symptoms, laryngitis, nasal congestion; Skin and Appendages—brittle fingernails, pruritus, rash, urticaria; Special Senses—blurred vision, conjunctivitis, ear-ache, scotoma; and Miscellaneous—bad taste, excessive salivation, leukopenia, malaise, sore throat/swollen neck glands, weight change.

A few rare events have been reported spontaneously worldwide since marketing in 1972. Although they occurred under circumstances in which a causal relationship with pentoxifylline could not be established, they are listed to serve as information for physicians: Cardiovascular—angina, arrhythmia, tachycardia; Digestive—hepatitis, jaundice; and Hemic and Lymphatic—decreased serum fibrinogen, pancytopenia, purpura, thrombocytopenia.

OVERDOSAGE:

Overdosage with Trental® (pentoxifylline) has been reported in children and adults. Symptoms appear to be dose related. A report from a poison control center on 44 patients taking overdoses of enteric-coated pentoxifylline tablets noted that symptoms usually occurred 4-5 hours after ingestion and lasted about 12 hours. The highest amount ingested was 80 mg/kg; flushing, hypotension, convulsions, somnolence, loss of consciousness, fever, and agitation occurred. All patients recovered.

In addition to symptomatic treatment and gastric lavage, special attention must be given to supporting respiration, maintaining systemic blood pressure, and controlling convulsions. Activated charcoal has been used to adsorb pentoxifylline in patients who have overdosed.

DOSAGE AND ADMINISTRATION:

The usual dosage of Trental® (pentoxifylline) in controlled-release tablet form is one tablet (400 mg) three times a day with meals.

While the effect of Trental® (pentoxifylline) may be seen within 2 to 4 weeks, it is recommended that treatment be continued for at least 8 weeks. Efficacy has been demonstrated in double-blind clinical studies of 6 months duration.

Digestive and central nervous system side effects are dose related. If patients develop these side effects it is recommended that the dosage be lowered to one tablet twice a day (800 mg/day). If side effects persist at this lower dosage, the administration of Trental® (pentoxifylline) should be discontinued.

Hoechst-Roussel Pharmaceuticals Inc.
Somerville, New Jersey 08876



A giant step toward compliance...

- Medication
- Diet
- Stopping smoking
- Exercise

Ask your Hoechst-Roussel representative for information about this innovative patient education program.



Trental® 400 mg Tablets
(pentoxifylline)

The only proven-effective agent for intermittent claudication symptomatic of peripheral arterial disease...

The name and logo HOECHST are registered trademarks of Hoechst AG.

NO TIMING, WIPING OR BLOTTING.

**Finally,
reliable blood glucose
monitoring
takes just
one touch.**



I N T R O D U C I N G

ONE TOUCHTM SYSTEM

A revolutionary blood glucose monitoring system from LifeScan.

**One Touch—
the first truly
simple system.**

The new One Touch System makes reliable blood glucose monitoring easier than ever. With One Touch, results can be achieved by touching the reagent pad just once—to apply blood—because no wiping or blotting is required.

**One Touch—no timing,
no wiping, no blotting,
no user demands.**

The One Touch System eliminates three major demands on your patients: starting the test, timing the test and removing the blood. With the test strip in the meter, the patient presses Power, then applies the blood sample to the reagent pad at any time. At this

1. Insert test strip.



2. Press POWER.





point the meter takes over, starting the test automatically when it detects blood on the reagent pad. No blood removal is required, and results appear in just 45 seconds. *The opportunity for procedural error is virtually eliminated.*

One Touch—easier to use, easier to handle.

The One Touch Meter provides a stable platform for the test strip while the blood sample

is applied. The reagent pad is smaller, so less blood is required for each test. The test strip is wider, so it's easier to handle.

One Touch—added features for greater convenience and confidence.

One Touch is the first blood glucose meter to provide interactive messages in plain English on a large, easy-to-read display.

With each One Touch test, numerous system self-checks (optics, software, memory function, strip presence and battery) are performed. And 250 previous test results may be recalled from memory.

One Touch—designed for technique-independent testing.

When blood glucose monitoring is kept simple, results are more reliable. The One Touch testing procedure accomplishes this goal.

3. Apply sample.



Result appears in just 45 seconds—with no timing, wiping, or blotting.

ONE TOUCH™
SYSTEM



The Complete One Touch™ System Includes:
 One Touch Meter with Carry Case
 One Touch Test Strips
 Penlet™ Automatic Sampling Pen and Lancets
 Glucose Control Solution
 Instructional Audio Cassette
 Owner's Booklet
 Logbook

Technology that tests the glucose, not the patient.

Specifications:

Fast test time

Results appear in just 45 seconds.

Wider dynamic range

0 to 600 mg/dL (0 to 33.3 mmol/L).

Unsurpassed accuracy

When compared to a clinical laboratory instrument (YSI Model 23A Glucose Analyzer) at three different clinical locations, results from patients using the One Touch System demonstrated excellent correlation with the reference method.

slope 1.02

y intercept 4.7 mg/dL

correlation coefficient (r) 0.979


Automatic memory

Stores most recent 250 readings. Data port for transferring memory contents to Data Manager™ unit for printed test histories with time and date.

Easy-to-read display

Alphanumeric; dot matrix LCD.

Comparison of One Touch used by patients vs. laboratory reference method*



Customer satisfaction guarantee

No risk money-back guarantee on One Touch System within 30 days of purchase. Full three-year warranty on One Touch Meter.

For a One Touch demonstration, contact your LifeScan Professional Representative. For the name of your local Representative, call toll-free:
In the U.S.: 1 800 227-8862
In Canada: 1 800 663-5521

*Data on file, LifeScan, Inc.

ONE TOUCH™

SYSTEM

LIFESCAN INC.

a Johnson & Johnson company
 Mountain View, California 94043

**TUNE IN. . .
NEWSLINE: NEW ORLEANS**



RIGHT IN YOUR HOTEL ROOM

6AM-9AM (VIA CLOSED CIRCUIT TELEVISION)

- ADA Scientific News
- Speaker Interviews
- Updates
- National Headlines
- Guest Program
- Local Weather

Sunday, June 12

Monday, June 13

Tuesday, June 14

FEATURED AT:

- Hilton Riverside & Towers
- Radisson Suite Hotel
- Marriott
- Hotel Meridien
- Doubletree Hotel
- Holiday Inn Crowne Plaza

Produced under an educational grant from:






ICI Pharmaceuticals Group

ICI Pharma
Stuart Pharmaceuticals
Divisions of ICI Americas Inc
Wilmington, Delaware 19897



American
Diabetes
Association, Inc.





D.A.W.

Master Plan for NIDDM Control

A Diabinese® (chlorpropamide) prescription completes the design

Diet, exercise, education and once-daily Diabinese®, dispensed as written, comprise the Master Plan for successful non-insulin-dependent diabetes mellitus (NIDDM) control. For overall NIDDM control, specify Diabinese® by name.

Proven Efficacy and Safety

In a two-year study comparing Diabinese® to glyburide, "...chlorpropamide was clinically more effective with a smaller number of primary and secondary drug failures and a greater proportion of patients successfully controlled at the end of 2 years. Severe hypoglycemia was a greater hazard during treatment with glyburide...."¹

As with all sulfonylureas, hypoglycemia may occur with Diabinese.

Once-a-day

Diabinese®

(chlorpropamide) Tablets, USP, 100 mg, 250 mg and D-Pak

A GENERATION AHEAD IN NIDDM CONTROL

Reference: 1. Clarke BF: Comparative effectiveness of glyburide in the treatment of non-insulin-dependent diabetes, in *Diagnosis and Management of Diabetes Mellitus*. Postgraduate Medicine: Custom Communications, April 1982, pp 57-65.

Please see Diabinese® (chlorpropamide) brief summary on the following page.

 **LABORATORIES DIVISION**
PFIZER INC. NEW YORK, N.Y. 10017



BRIEF SUMMARY
DIABINESE® (chlorpropamide)
TABLETS, USP

CONTRAINDICATIONS

DIABINESE is contraindicated in patients with:
1. Known hypersensitivity to the drug.
2. Diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.

WARNINGS

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY

The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (*Diabetes*, 19 (suppl. 2):747-830, 1970).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2½ times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of DIABINESE (chlorpropamide) and of alternative modes of therapy.

Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

PRECAUTIONS

General

Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Proper patient selection, dosage, and instructions are important to avoid hypoglycemic episodes. Renal or hepatic insufficiency may cause elevated blood levels of DIABINESE and the latter may also diminish gluconeogenic capacity, both of which increase the risk of serious hypoglycemic reactions. Elderly, debilitated or malnourished patients, and those with adrenal or pituitary insufficiency are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used.

Because of the long half-life of chlorpropamide, patients who become hypoglycemic during therapy require careful supervision of the dose and frequent feedings for at least 3 to 5 days. Hospitalization and intravenous glucose may be necessary.

Loss of control of blood glucose: When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a loss of control may occur. At such times, it may be necessary to discontinue DIABINESE (chlorpropamide) and administer insulin.

The effectiveness of any oral hypoglycemic drug, including DIABINESE, in lowering blood glucose to a desired level decreases in many patients over a period of time, which may be due to progression of the severity of the diabetes or to diminished responsiveness to the drug. This phenomenon is known as secondary failure, to distinguish it from primary failure in which the drug is ineffective in an individual patient when first given.

ADVERSE REACTIONS

Hypoglycemia: See PRECAUTIONS section.

Gastrointestinal Reactions: Cholestatic jaundice may occur rarely; DIABINESE should be discontinued if this occurs. Gastrointestinal disturbances are the most common reactions; nausea has been reported in less than 5% of patients, and diarrhea, vomiting, anorexia, and hunger in less than 2%. Other gastrointestinal disturbances have occurred in less than 1% of patients including proctocolitis. They tend to be dose related and may disappear when dosage is reduced.

Dermatologic Reactions: Pruritus has been reported in less than 3% of patients. Other allergic skin reactions, e.g., urticaria and maculopapular eruptions have been reported in approximately 1% or less of patients. These may be transient and may disappear despite continued use of DIABINESE (chlorpropamide); if skin reactions persist the drug should be discontinued.

Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas.

Skin eruptions rarely progressing to erythema multiforme and exfoliative dermatitis have also been reported.

Hematologic Reactions: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, pancytopenia, and eosinophilia have been reported with sulfonylureas.

Metabolic Reactions: Hepatic porphyria and disulfiram-like reactions have been reported with DIABINESE.

Endocrine Reactions: On rare occasions, chlorpropamide has caused a reaction identical to the syndrome of inappropriate antidiuretic hormone (ADH) secretion. The features of this syndrome result from excessive water retention and include hyponatremia, low serum osmolality, and high urine osmolality.

DOSAGE AND ADMINISTRATION

There is no fixed dosage regimen for the management of diabetes mellitus with DIABINESE or any other hypoglycemic agent. In addition to the usual monitoring of urinary glucose, the patient's blood glucose must also be monitored periodically to determine the minimum effective dose for the patient; to detect primary failure, and to detect secondary failure. Glycosylated hemoglobin levels may also be of value in monitoring the patient's response to therapy.

The total daily dosage is generally taken at a single time each morning with breakfast. Occasionally cases of gastrointestinal intolerance may be relieved by dividing the daily dosage. A LOADING OR PRIMING DOSE IS NOT NECESSARY AND SHOULD NOT BE USED.

Initial Therapy: 1. The mild to moderately severe, middle-aged, stable, non-insulin-dependent diabetic patient should be started on 250 mg daily. Older patients should be started on smaller amounts of DIABINESE (chlorpropamide), in the range of 100 to 125 mg daily.

2. No transition period is necessary when transferring patients from other oral hypoglycemic agents to DIABINESE. The other agent may be discontinued abruptly and chlorpropamide started at once. In prescribing chlorpropamide, due consideration must be given to its greater potency.

Many mild to moderately severe, middle-aged, stable non-insulin-dependent diabetic patients receiving insulin can be placed directly on the oral drug and their insulin abruptly discontinued. For patients requiring more than 40 units of insulin daily, therapy with DIABINESE may be initiated with a 50 per cent reduction in insulin for the first few days, with subsequent further reductions dependent upon the response.

Five to seven days after the initial therapy, the blood level of chlorpropamide reaches a plateau. Dosage may subsequently be adjusted upward or downward by increments of not more than 50 to 125 mg at intervals of 3 to 5 days to obtain optimal control. More frequent adjustments are usually undesirable.

Maintenance Therapy: Most moderately severe, middle-aged, stable non-insulin-dependent diabetic patients are controlled by approximately 250 mg daily. Many investigators have found that some milder diabetics do well on daily doses of 100 mg or less. Many of the more severe diabetics may require 500 mg daily for adequate control. PATIENTS WHO DO NOT RESPOND COMPLETELY TO 500 MG DAILY WILL USUALLY NOT RESPOND TO HIGHER DOSES. MAINTENANCE DOSES ABOVE 750 MG DAILY SHOULD BE AVOIDED.


HOW SUPPLIED

Blue, 'D'-shaped, scored tablets in strengths of 100 mg, tablet code 393; (100's, NDC #0663-3930-66; 500's, NDC #0663-3930-73; and 100 unit dose of 10 X 10, NDC #0663-3930-41) and 250 mg, tablet code 394; (100's, NDC #0663-3940-66; 250's, NDC #0663-3940-71; 1000's, NDC #0663-3940-82; 100 unit dose of 10 X 10, NDC #0663-3940-41; and 30's D-Pak, NDC #0663-3940-30).

RECOMMENDED STORAGE: Store below 86°F (30°C).

CAUTION: Federal law prohibits dispensing without prescription.

 **LABORATORIES DIVISION**
PFIZER INC., NEW YORK, N.Y. 10017



Preserve your copies of diabetes

These journal slippcases and binders turn back issues into a permanent reference source.

Bound in attractive blue leatherette, and embossed with gold lettering, one slippcase or two binders holds 1 year of DIABETES

(12 issues plus supplements). These durable, space saving cases make affordable gifts as well!

SLIPCASES: \$7.95 each, three for \$21.95, six for \$39.95

BINDERS: \$9.95 each, three for \$27.95, six for \$52.95

MAIL TO: Jesse Jones Industries, Dept. DIAB
499 East Erie Avenue, Philadelphia, PA 19134

Please send _____ cases; _____ binders.

Enclosed is \$_____. Add \$1 per item for Postage and Handling. Outside U.S.A. add \$2.50 per item (U.S. funds only).

Print Name _____

Address _____

No P.O. Boxes Please

City/State/Zip _____

PA residents add 6% sales tax

We also accept American Express, Visa, MasterCard and Diners Club (for minimum orders of \$15.00). Call TOLL FREE (charge orders only) 1-800-972-5858, 7 days, 24 hours.

NOTE: Satisfaction guaranteed. Slippcase and binders are also available for DIABETES CARE & DIABETES FORECAST.

For information write:

American Diabetes Association,
1660 Duke St., Alexandria, VA 22314,
Attn: Circulation Dept.



 **AMERICAN DIABETES ASSOCIATION**
MISSING ISSUE
POLICY

Replacements for missing issues will be sent free of charge provided we are notified within two months of the issue date for U.S. and Canadian subscribers/members or within four months of the issue date for all other foreign subscribers/members.

To order back issues, please prepay in U.S. funds drawn on a U.S. bank.

Diabetes and Diabetes Care
(Single copy price)

U.S.	Foreign Surface Mail	Foreign Air Mail
\$8.00	\$10.50	\$14.00

Make check payable to:

American Diabetes Association
Back Issue Department
1660 Duke Street
Alexandria, VA 22314

Look to Lea & Febiger for the best books on diabetes and related topics

ENDOCRINE PATHOPHYSIOLOGY: A Patient-Oriented Approach, 3rd ed.

Edited and with contributions by JEROME M. HERSHMAN, M.D., *University of California at Los Angeles School of Medicine, Los Angeles, California.* Emphasizes a functional understanding of pathophysiology and disease mechanisms as the basis for effective diagnosis. 365 pp., 87 illus., paperback, 1988, \$19.50.

THE SKIN IN DIABETES

Edited and with contributions by J.E. JELINEK, M.D., *New York University Medical Center, New York, New York.* Authoritative sections review diabetic markers including necrobiosis lipoidica diabetorum, diabetic dermopathy, diabetic bullae, and eruptive xanthomas. 237 pp. (7 x 10), 103 illus. (9 plates in full color), 1986, \$33.50.

MODERN NUTRITION IN HEALTH AND DISEASE, 7th ed.

Edited by MAURICE E. SHILS, M.D., Sc.D., *Cornell University Medical College, New York, New York;* and VERNON R. YOUNG, Ph.D., *Massachusetts Institute of Technology, Cambridge, Massachusetts.* Effectively presents advances in the science and practice of nutrition. 1694 pp. (7 1/4 x 10 1/4), 400 illus., 1988, \$75.00.

SURGICAL DISEASES OF THE PANCREAS

Edited and with contributions by JOHN M. HOWARD, M.D., *Medical College of Ohio at Toledo, Toledo, Ohio;* GEORGE L. JORDAN, JR., M.D., *Baylor College of Medicine, Houston, Texas;* and HOWARD A. REBER, M.D., *UCLA School of Medicine, Los Angeles, California.* Covers recent and rapid progress in understanding pancreatic diseases, and the encouraging developments in therapy. 958 pp. (7 1/4 x 10 1/4), 317 illus. (including 1 in color), 1987, \$145.00.

JOSLIN'S DIABETES MANUAL, 12th ed.

By LEO P. KRALL, M.D., *and* RICHARD BEASER, M.D., *both of Joslin Diabetes Center, Boston, Massachusetts.*

A NEW EDITION OF THE BEST SELLING MANUAL...

HIGHLY REGARDED BY PATIENT AND PHYSICIAN ALIKE!

The quickening pace of progress in diabetes research and patient care is expertly detailed in a significant revision of this proven, time-honored guide to diabetes. What diabetes is, how to effectively cope with the limitations it imposes, plus the specifics on traditional and new methods of management are all spelled out with an entirely readable, patient-oriented approach.

- Both conventional means of treatment and the new intensive insulin therapy, including the use of insulin pumps are explained.
- New chapters focus on diabetes in exercise, pregnancy, and aging.
- The 12th edition updates the important subject of diet with information of fiber, low fat, and consumer-oriented lists of sweeteners and types of food.

These journals have enthusiastically recommended past editions of Joslin Diabetes Manual, 12th ed. to the patient and physician! "The writing style is intriguing, the information factual, and the overall presentation laudable..."

This book gives you an in-depth explanation of all aspects of diabetes. It is more comprehensive than any other manual. THE BEST! *Diabetes Newsletter* About 450 pp. (5 7/8 x 9 1/4), 51 illus., paperback, September 1988, In Prep. \$10.95.

JOSLIN'S DIABETES MELLITUS, 12th ed.

Edited and with contributions by ALEXANDER MARBLE, M.D., LEO P. KRALL, M.D., ROBERT F. BRADLEY, M.D., A. RICHARD CHRISTLIEB, M.D., *and* J. STUART SOELDNER, M.D., *all of the Joslin Clinic, Boston, Massachusetts.* In-depth information and guidance for clinicians, clinical investigators and allied health professionals with new chapters on: epidemiology; immunology; animal models; metabolic fuels; sexual disorders; exercise; education; diabetes in the elderly; and hypertension. This edition provides a wealth of practical information regarding current clinical and investigative aspects of diabetes. 1010 pp. (7 1/4 x 10 1/4), 168 illus. (plus 1 color illus. and 6 color plates), 1985, \$80.00.



CALL TOLL FREE 1-800-433-3850

(USA only, except PA, AK, HI)

Use your MasterCard, VISA or American Express card to order.

Plan now to visit our booth at the American Diabetes Association meeting in New Orleans, June 11-14.

Quality Publishers Since 1785



LEA & FEBIGER

600 WASHINGTON SQUARE
PHILADELPHIA, PENNSYLVANIA 19106-4198
PHONE: (215) 922/1330 / 1-800-433-3850

Amazingly Enough, This
Blood Glucose Meter's
Biggest Breakthrough
Isn't Size.



Baxter

It's Accuracy.

Presenting the ExacTech™ Blood Glucose Meter.

It's accurate because it's less dependent on user technique.

Technique-dependent steps like wiping, blotting, timing and cleaning have been eliminated. In fact, because this meter is so easy to use, patients are inclined to test themselves regularly.

They simply insert a test strip into the meter, put a small drop of blood on the target area and press the button. Results appear on the display in just 30 seconds.

It's all due to our exclusive system. One part is



the ExacTech Meter, which determines blood glucose levels through a unique electronic measuring method. The other is the ExacTech Test Strip, which has a small, hydrophilic target area that attracts blood.

At last, there's been a breakthrough in meter technology. Recommend it to your patients. Call 1-800-527-3339, ext. 700, for more information, or write Baxter Healthcare Corporation, Physician Diagnostics Division, Attn: ExacTech, 1415 Lake Cook Road, P.O. Box 852, Deerfield, Illinois 60015-0852.

We're committed to helping people with diabetes live better lives.



FACULTY POSITION IN
DIABETES AND
METABOLISM RESEARCH
MAYO CLINIC AND FOUNDATION

The Endocrine Research Unit has an unparalleled career opportunity for a highly qualified person (Ph.D., M.D., or M.D./Ph.D.) to develop an independent research program in diabetes mellitus and related metabolic disorders. Candidates should have had advanced training in basic biochemistry, in such areas as membrane or receptor biochemistry, molecular biology, immunology, or mechanisms of hormone action.

The Endocrine Research Unit has six NIH-funded staff investigators (4 in diabetes/metabolism, and 2 in bone/mineral research), training grant support, ample modern research space and equipment, and active collaborations with members of other departments. Startup funds are available for establishment of the new laboratory programs. Mayo Medical Center encompasses the Mayo Clinic, Mayo Medical School, and the Mayo Graduate School of Medicine. This is a career research opportunity with a strong, active, multidisciplinary group.

Qualified candidates should submit detailed curricula vitae, bibliographies, and names of three references to:

Hunter Heath III, M.D.
Chairman, Endocrine Search Committee
Mayo Clinic
5-164 West Joseph Building
Rochester, MN 55905
(Telephone 507-285-4300)



AN EQUAL OPPORTUNITY/AFFIRMATIVE ACTION EMPLOYER

CLASSIFIED ADVERTISING

Diabetes Classified Ad rates are:

¼ Page \$370
(for non-ADA members, \$495)

⅓ Page \$180
(for non-ADA members, \$250)

All advertising must be prepaid
with order.

All advertisements will be
typeset uniformly.

The closing date for space in
Diabetes is: the first of the month
preceding month of publication;
(December 1st for the January
issue).


Circulation: 9,000 Paid

For information on classified
advertising in *Diabetes Care* and
Diabetes Spectrum; and Copy and
Contract Policies, contact:

Peggy B. Donovan
American Diabetes Association
1660 Duke Street
Alexandria, VA 22314

(800) 232-3472 ext. 312 or in Virginia
and the Washington, DC area dial
(703) 549-1500.

**FIGHT
HEART DISEASE
KIDNEY DISEASE
AND BLINDNESS
IN ONE STROKE.**



Diabetes is a major contributor to heart disease, kidney disease, and blindness. So when you support the American Diabetes Association, you fight some of the worst diseases of our time. See the White Pages for the American Diabetes Association office nearest you or call 1-800-ADA-DISC


FIGHT SOME OF THE WORST DISEASES OF OUR TIME.
Support the American Diabetes Association.

Filling your plate has never been easier.

Discover these delicious new ways to enjoy every meal!

Imagine . . . taste-tempting meals that are also good for you! From everyday meal planning to special events, ADA makes your task easier with these new publications . . .

Easy-to-follow nutritional guidelines you can use every day.




This new, updated version of our best-selling meal planner, *Exchange Lists for Meal Planning* brings you the latest scientific findings on good nutrition and healthful eating. Colorful charts, helpful tips on

good nutrition, and easy-to-use substitution guidelines show you how to balance your diet and gain control over diabetes.



Reprints of popular articles from *Diabetes Forecast*

A package of ten best sellers including "Think Thin," "Whiskey or Water?" and "Hamburgers to Haute Cuisine," are now available offering you timely important tips to meal planning.




Enticing new recipes for you and your family.

The American Diabetes Association/The American Dietetic Association Family Cookbooks (Volumes I and II) Designed to meet the special needs of people with diabetes and their families, these comprehensive companion volumes combine to give you more than 450 imaginative,



kitchen-tested recipes available from no other source. Plus you'll find innovative nutrients-per-serving guidelines, important tips on eating out . . . brown-bagging . . . exercise, and more! (Individual volumes may be purchased separately.)

The American Diabetes Association Holiday Cookbook Now you can enjoy the holidays more than ever before with these festive recipes tailored for individuals and families living with diabetes. From traditional Thanksgiving, Christmas and Hanukkah feasts . . . to refreshing beverages and savory dinners for any occasion, you'll receive more than 175 tempting new recipes for appetizers, salads, soups . . . even bread and cookies! And you'll regularly refer to the *newly revised* exchange equivalents, and chapters on adjusting your favorite family recipes to reduce sugar, fats, and sodium.



Start eating better today!

Yes, please send me copies of the following publications as checked (make checks payable to the American Diabetes Association):

No. of Copies	Title	Total
_____	<i>Exchange Lists for Meal Planning</i> , \$1.75 each	\$_____
_____	Packages of Ten Reprints from <i>Diabetes Forecast</i> , \$3.60 each	\$_____
_____	<i>The American Diabetes Association/The American Dietetic Association Family Cookbook</i> , Vol. I. @ \$17.45	\$_____
_____	<i>The American Diabetes Association/The American Dietetic Association Family Cookbook</i> , Vol. II. @ \$18.45	\$_____
_____	<i>The American Diabetes Association Holiday Cookbook</i> , @ \$16.45	\$_____
Total Amount Enclosed		\$_____

(All prices include postage and handling)


Name _____
Address _____
City _____
State _____
Zip _____


Send your order to:

The American Diabetes Association
1660 Duke Street
Alexandria, VA 22314
(800) ADA-DISC

Please allow 6-8 weeks for delivery.

FREE bonus copy of Healthy Food Choices with your order!





More than 10 million people with type II diabetes are depending on you.

Are you up-to-date?

With the rapid advances being made in diabetes, it is essential that you have the latest source of information about type II diabetes—to give your patients the best care possible. The American Diabetes Association recognizes this need and has now revised the popular Physician's Guide to Non-Insulin Dependent (Type II) Diabetes, to reflect important new changes learned during the past four years.

In this second edition, you will find major changes in the sections about:

- pathogenesis;
- management; and
- detection and treatment of complications.

For example, there are new guidelines for the control of lipid and cholesterol levels and a presentation of new approaches to diabetic complications.

Take it from the experts...

Marvin E. Levin, MD, a clinical professor of medicine, Washington University, and a practicing diabetologist, remarks: "Here is the very latest findings on this most common type of diabetes including an excellent and concise approach to therapy."

It's the most practical, succinct, readable, and easy-to-use guide that you'll find for the diagnosis and treatment of non-insulin-dependent diabetes.

**1988 EDITION
UPDATED AND REVISED**

**Physician's Guide to
Non-Insulin-Dependent
(Type II) Diabetes
Diagnosis and
Treatment
Second Edition**

**Diagnosis and Classification
of Diabetes Mellitus**

Highlights
Introduction
Types of Diabetes Mellitus and Other Categories of
Glucose Intolerance
Clinical Classes
- Diabetes Mellitus
- Impaired Glucose Tolerance
- Gestational Diabetes Mellitus
Statistical Risk Classes
Diagnosis of Diabetes Mellitus and Other Categories of
Glucose Intolerance
Indications and Criteria for Screening Tests
Indications for Diagnostic Testing
Diagnostic Tests for Diabetes Mellitus
Criteria for Diagnosis of Diabetes Mellitus
Diagnosis in Nonpregnant Adults
Diagnosis in Children
Oral Glucose Tolerance Test
Criteria for Diagnosis of Gestational Diabetes
Evaluation and Classification of Patients
Before Treatment
Evaluation of the Patient
Classification of the Patient
Special Problems in Classification
Reclassification of the Patient

YES! Bring me up-to-date.

Please send me the new second edition *Physician's Guide to Non-Insulin-Dependent (Type II) Diabetes: Diagnosis and Treatment*.

I am a member of the ADA and want to take advantage of my membership discount. My membership number is _____ (appears on your DIABETES FORECAST label)

Nonmember Price **\$19.95** per copy Member Price **\$15.95** per copy
(PLUS \$2.50 FOR SHIPPING AND HANDLING.)

_____ Copies @ \$_____ per copy + \$2.50 (S&H) = \$_____ **TOTAL**

Name _____


Address _____

City _____

State _____ Zip _____

Phone () _____ **HK01**

Thank you. All checks or money orders must be paid in U.S. dollars, drawn on a U.S. bank to the American Diabetes Association, Attn: Order Dept., 1660 Duke St., Alexandria, VA 22314. Add \$2.50 to the book price for shipping and handling. Prices are subject to change without notice. Allow 6 to 8 weeks for domestic delivery and add appropriate time for foreign surface delivery.



The International Diabetes Federation

SERVING DIABETES PROFESSIONALS AROUND THE WORLD.

Diabetes is a worldwide disease. It has no nationality.

For the past 30 years, the International Diabetes Federation has been helping all those involved in diabetes research, treatment and education by providing the most appropriate and relevant information about the latest world wide developments in diabetes care.

If your professional work demands that you stay on top of these developments, you should become an IDF member.

Your membership will bring you three issues of the IDF's newly expanded official publication, the **IDF Bulletin**. In each issue, you will receive previews of important work-in-progress around the world, plus behind-the-scenes views of diabetes treat-



ment in different socioeconomic environments and cultures.

Nowhere else can researchers, practitioners, and educators from different continents speak directly to each other and examine such important areas as:

- Diabetes in Youth
- Diabetes in Maternal and Child Health
- Diabetes in Developing Countries
- Complications of Diabetes
- Professional and Patient Education
- Basic and Applied Research

The International Diabetes Federation is committed to forging a link among diabetes experts worldwide in the fight to conquer diabetes.

LEADERS IN THE FIELD REPORT THE LATEST ADVANCES IN...

The IDF Bulletin

Special topics for 1987 included:



August 1987
SPECIAL SYMPOSIUM ISSUE ON ORAL HYPOGLYCEMIC AGENTS

October 1987
A GLOBAL VIEW OF DIABETES COMPLICATIONS
H. Keen, M.D.
H. Rifkin, M.D.

December 1987
DIABETES IN GENERAL PRACTICE
F. Puchulu, M.D.
A. Samad Shera, M.D.

Special topics scheduled for the 1988 IDF BULLETIN will include: **TREATMENT OF DIABETES IN DEVELOPING COUNTRIES, AND THE SPECIAL 13th IDF CONGRESS ISSUE.**

IDF ORDER FORM

You can receive the three 1988 issues of the **IDF Bulletin** by becoming a member of the International Diabetes Federation. You'll also receive reduced fees to IDF events and preferred subscription rates to other diabetes journals. To become a member, simply check the box below.

Please enroll me as a member of the International Diabetes Federation. 1-year membership: \$20.00.

Name _____
Address _____
City _____
State _____
Zip _____

Please send your \$20.00 check, made payable to the International Diabetes Federation, to:
The International Diabetes Federation
c/o American Diabetes Association
1660 Duke Street
Alexandria, VA 22314


Announcing . . .

Clinical Diabetes Reviews

The American Diabetes Association has created this compendium of up-to-date articles from its two internationally recognized clinical journals—*Diabetes Care* and *Clinical Diabetes*. This indispensable softcover book provides you with the latest developments in diabetes treatment . . . so you can provide your patients with the best care possible.

Clinical Diabetes Reviews contains 29 jargon-free articles written for you by world-renowned experts in the field of diabetes. Its 208 pages offer you the most thorough analysis, in a single volume, covering all these important areas:

- **Diagnosis**
- **Pathogenesis**
- **Psychosocial Aspects**
- **Special Problems and Complications**
- **Routine Management**
- **Drug Therapy**



Yes!

Please send me *Clinical Diabetes Reviews*, Vol. 1. I have enclosed a check for the following:

	Price	No. of Copies	(VA residents only add 4%) Tax	Total
Member	\$15.95	× _____	+ _____	= _____
Nonmember	\$19.95	× _____	+ _____	= _____


ADA Member # from my magazine label _____
 Name _____
 Organization _____
 Address _____
 City _____ State _____ Zip _____

Make checks payable to:

American Diabetes Association
 1660 Duke Street
 Alexandria, VA 22314

HLO1

Preserve your copies of DIABETES CARE®



Custom-made for DIABETES CARE, these journal slipcases and binders turn back issues into a permanent reference source. Bound in attractive blue leatherette, and embossed with gold lettering, each slipcase and binder holds 1 year of DIABETES CARE (6 issues plus supplement). And each comes with gold transfers, allowing you to personalize your volume further. These durable, space saving cases make affordable gifts as well.

SLIPCASES: \$7.95 each, three for \$21.95, six for \$39.95 (measures: 11½ × 8½ × 2 1/8")

BINDERS: \$9.95 each, three for \$27.95, six for \$52.95 (measures: 12¾ × 9¼ × 3½")

MAIL TO: Jesse Jones Industries, Dept. DIAB-C
 499 East Erie Avenue, Philadelphia, PA 19134

Please send _____ cases; _____ binders.

Enclosed is \$_____. Add \$1 per item for Postage and Handling. Outside U.S.A. add \$2.50 per item (U.S. funds only).

Print Name _____

Address _____

No P.O. Boxes Please

City/State/Zip _____

PA residents add 6% sales tax

We also accept American Express, Visa, MasterCard and Diners Club (for minimum orders of \$15.00). Call TOLL FREE (charge orders only) 1-800-972-5858, 7 days, 24 hours.

NOTE: Satisfaction guaranteed. Slipcase and binders are also available for DIABETES & DIABETES FORECAST.

For information write:

American Diabetes Association,
 1660 Duke St., Alexandria, VA 22314,
 Attn: Circulation Dept.



Your source for progress in controlling the complications of diabetes



Center for Advanced Study in Complications of Diabetes

The new Center for Advanced Study in Complications of Diabetes (CASCD) has a crucial mission: to provide you with up-to-date information on the prevention and treatment of complications of diabetes.

We're at the forefront of research in this area, and as information emerges, we'll be sending you scientific and clinical updates to help build your clinical expertise. You will be able to turn to CASCD for comprehensive answers when you have questions about such evolving issues as aldose-reductase inhibition, the pathogenesis of diabetic complications, and new

developments in diagnosis and treatment.

As the companies who have consistently innovated in international health care... most notably with the introduction of beta blockade to cardiovascular disease, the first antiestrogen therapy in oncology, and major advances in anesthesia... we're committed to progress in control of the complications of diabetes. The formation of CASCD, together with our continuing clinical research, signals the depth of that commitment. Through it, we hope that one day the promise of this intensive effort will become a clinical reality.


*Committed to improving the control
of diabetic complications*



STUART PHARMACEUTICALS
Division of ICI Americas Inc.
Wilmington, Delaware 19897



ICI PHARMA
Division of ICI Americas Inc.
WILMINGTON, DELAWARE 19897 USA



FREE ADA Information for You and Your Patients

Available FREE:

Diabetes '88
 Receive 10 FREE copies of EVERY ISSUE of **Diabetes '88**, ADA's quarterly patient newsletter*. Each 12-page issue is filled with basic information on living with diabetes, including tips on diet, exercise, and diabetes management.

ADA General Membership Pad
 Tell your patients about the benefits of joining the American Diabetes Association with a page from our 50-sheet Membership Pad.

The above items are FREE and available now. Complete the form and mail it today to receive your FREE ADA information.

***NOTE:** Diabetes '88 is available to people living in the U.S. only.

The American Diabetes Association wants you to know about the FREE materials available to you, your patients, their families—everyone that you encounter who needs information and advice on diabetes.

Choose the FREE issues of **Diabetes '88** or the FREE Membership Pad—or choose both. Help your patients to receive the important information they need with **Diabetes '88**, and to enjoy the benefits of membership in the American Diabetes Association with the General Membership Pad. General Membership benefits include:

- One-year subscription to **Diabetes Forecast** (12 issues), the big, colorful members' magazine filled with in-depth articles on diabetes management, research, celebrities and everyday heroes who don't let diabetes stand in the way of personal achievement, and much more.
- Membership in a nearby ADA Affiliate. Local ADA Affiliates provide lectures, workshops, counseling, summer camps and other services not available anywhere else—and the chance to meet other people with diabetes.
- Mailed newsletter from the ADA Affiliate listing diabetes-related events and educational programs in the area.
- A vote in the Association's local elections.

Please fill out the form below and return it to the ADA—today!

YES! I want my patients to receive the FREE information and the benefits of the American Diabetes Association. Please send me:


- _____ FREE copies of each issue of **Diabetes '88**. (10 or more copies of each issue are available FREE. Please indicate your need.)
- _____ FREE 50-sheet Membership Pad. (1 only)



Return to: **American Diabetes Association**
 DIABETES '88
 P.O. Box 2055
 Harlan, IA 51593-0238

Name _____
 Organization _____
 Address _____
 City _____ State _____ Zip _____

Exceptional New References on Endocrinology and Metabolism



Kinney, Jeejeebhoy, Hill, & Owen **NUTRITION AND METABOLISM IN PATIENT CARE**

Written specifically for physicians, this authoritative reference provides you with the most detailed and scientific review of nutrition and metabolism in its field! Examines the role of nutritional support disease-by-disease in over 30 clinical specialties.

By *John M. Kinney*, MD, Prof. Emeritus in Surgery, Columbia Univ.; Visiting Prof., Rockefeller Univ.; Attending in Med., & Surgery, St. Luke's-Roosevelt Hosp. Ctr., NY; *K.N. Jeejeebhoy*, MB, BS, Prof. of Med., Univ. of Toronto; Chief of Gastroenterology, Toronto Gen. Hosp., Toronto; *Graham L. Hill*, MD, Prof. & Chairman, Univ. Dept. of Surgery, Auckland Hosp., Auckland; and *Oliver E. Owen*, MD, Prof. of Med., Temple Univ. School of Med.; Program Dir., Gen. Clinical Research Ctr., Temple Univ. Hosp., Philadelphia. 797 pp. 405 ills. 1988. \$125.00. W1156-7.

DeGroot **ENDOCRINOLOGY, 2nd Edition**

Completely revised and updated, the second edition (now in 3 volumes) reflects the latest advances in molecular biology and therapeutics. Written by world experts, it integrates biochemistry with clinical medicine to provide the definitive reference work for endocrinologists in practice. New coverage includes the latest developments in estrogen, thyroid, and glucocorticoid receptors, and much more!

By *Leslie J. DeGroot*, MD, Prof. of Med., Head of Endocrine Section, Univ. of Chicago, IL. Over 2800 pp. Available September 1988. 3-Vol.-Set \$295.00. W2222-4.

Metz & Benson **MANAGEMENT AND EDUCATION OF THE DIABETIC PATIENT**

Written by a distinguished clinical team, this outstanding text presents a practical, up-to-date approach to diabetes practice and education. Examines and identifies four major areas of diabetes management: 1) basic information; 2) management; 3) complications; and 4) diabetes education.

By *Robert Metz*, MD, MB, BCh, Ch. PhD; and *James W. Benson, Jr.*, MD, both of Dept. of Med., Section of Endocrinology & Metabolism, The Mason Clinic, Seattle, WA. 247 pp. Illustd. 1988. \$22.95. W1945-2.

Benson, Brown & Tasman **DIABETES AND ITS OCULAR COMPLICATIONS**

W.B. SAUNDERS is proud to announce an invaluable clinical tool for eye specialists — **Diabetes and Its Ocular Complications!** Provides authoritative coverage on all retinal and non-retinal diabetic eye diseases, with special emphasis on pathogenesis. It's the perfect reference for ophthalmologists, diabetologists, internists, opticians, plus family and general practitioners!

By *William E. Benson*, MD, Attending Surgeon, Wills Eye Hosp., Philadelphia, PA; Prof. of Ophthalmology, Thomas Jefferson Univ. School of Med., Philadelphia, PA. *Gary C. Brown*, MD, Assoc. Surgeon, Wills Eye Hosp.; Assoc. Prof. of Ophthalmology, Thomas Jefferson Univ. School of Med.; and *William Tasman*, MD, Ophthalmologist-in-Chief, Wills Eye Hosp.; Chairman, Dept. of Ophthalmology, Thomas Jefferson Univ. Hosp. 213 pp. 378 ills. 1988. \$65.00. 14263-6.

Call Toll Free 1-800-782-4479
8:30 to 5:00 Eastern Time to order!
(In Fla. call 1-407-345-2525)
Be sure to mention DM#05770!
OR



Clip and mail this no-risk coupon today!

W.B. SAUNDERS

YES! Please rush my copy of the books checked below. If not completely satisfied, I may return the books with the invoice within 30 days at no further obligation. I am returning this order form to: W.B. SAUNDERS, Order Fulfillment Department, Orlando, Florida 32887.

- W1156-7 Kinney et al \$125.00 W1945-2 Metz & Benson \$22.95
 W2222-4 DeGroot \$295.00 14263-6 Benson et al \$65.00

- Bill me (plus postage and handling and applicable sales tax)
 Check enclosed including applicable sales tax (publisher pays postage & handling)
 Charge my credit card including applicable sales tax (publisher pays postage & handling)

VISA MasterCard Exp. date _____
My credit card # is _____

_____/_____/_____/_____/_____

Full Name _____

Address _____

City _____ State _____ Zip _____

© W.B. SAUNDERS 1988.
Professional references may be tax-deductible.
Offer valid in USA only. Prices subject to change without notice. Diabetes 5/88 DM05770

W.B. SAUNDERS

Harcourt Brace Jovanovich, Inc.



First hundreds...

Then thousands...

Soon more than a million.

Soon more than a million insulin users will be taking Humulin.

And no wonder. Humulin is identical to the insulin produced by the human pancreas—except that it is made by rDNA technology.

Humulin is not derived from animal pancreases. So it contains none of the animal-source pancreatic impurities that may contribute to insulin allergies or immunogenicity.

The clinical significance of insulin antibodies in the complications of diabetes is uncertain at this time. However, high antibody titers have been shown to decrease the small amounts of endogenous insulin secretion some insulin users still have. The lower immunogenicity of Humulin has been shown to result in lower insulin antibody titers; thus, Humulin may help to prolong endogenous insulin production in some patients.

Any change of insulin should be made cautiously and only under medical supervision. Changes in refinement, purity, strength, brand (manufacturer), type (regular, NPH, Lente®, etc), species/source (beef, pork, beef-pork, or human), and/or method of manufacture (recombinant DNA versus animal-source insulin) may result in the need for a change in dosage.

DIET...EXERCISE...

Humulin® 
 human insulin
 (recombinant DNA origin)

For your insulin-using patients



Lilly Leadership
 IN DIABETES CARE



Eli Lilly and Company
 Indianapolis, Indiana
 46285